000127437 001__ 127437
000127437 005__ 20240228140927.0
000127437 0247_ $$2doi$$a10.1007/s11060-015-1758-5
000127437 0247_ $$2pmid$$apmid:25820321
000127437 0247_ $$2ISSN$$a0167-594X
000127437 0247_ $$2ISSN$$a0167-594x
000127437 0247_ $$2ISSN$$a1573-7373
000127437 037__ $$aDKFZ-2017-03460
000127437 041__ $$aeng
000127437 082__ $$a610
000127437 1001_ $$aSandén, Emma$$b0
000127437 245__ $$aAberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas.
000127437 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2015
000127437 3367_ $$2DRIVER$$aarticle
000127437 3367_ $$2DataCite$$aOutput Types/Journal article
000127437 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1508849505_27284
000127437 3367_ $$2BibTeX$$aARTICLE
000127437 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127437 3367_ $$00$$2EndNote$$aJournal Article
000127437 520__ $$aThe CD24 glycoprotein is a mediator of neuronal proliferation, differentiation and immune suppression in the normal CNS, and a proposed cancer biomarker in multiple peripheral tumor types. We performed a comparative analysis of CD24 gene expression in a large cohort of pediatric and adult brain tumors (n = 813), and further characterized protein expression in tissue sections (n = 39), primary brain tumor cultures (n = 12) and a novel orthotopic group 3 medulloblastoma xenograft model. Increased CD24 gene expression was demonstrated in ependymomas, medulloblastomas, anaplastic astrocytomas and glioblastomas, although medulloblastomas displayed higher expression than all other tumor entities. Preferential expression of CD24 in medulloblastomas was confirmed at protein level by immunostaining and computerized image analysis of cryosections. Morphologies and immunophenotyping of CD24(+) cells in tissue sections tentatively suggested disparate functions in different tumor subsets. Notably, protein staining of medulloblastoma cells was associated with prominent cytoplasmic and membranous granules, enabling rapid and robust identification of medulloblastoma cells in clinical tissue samples, as well as in experimental model systems. In conclusion, our results implicate CD24 as a clinically and experimentally useful medulloblastoma immunomarker. Although our results encourage further functional studies of CD24 as a potential molecular target in subsets of brain tumors, the promiscuous expression of CD24 in vivo highlights the importance of specificity in the future design of such targeted treatment.
000127437 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000127437 588__ $$aDataset connected to CrossRef, PubMed,
000127437 650_7 $$2NLM Chemicals$$aAntigens, CD24
000127437 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000127437 650_7 $$2NLM Chemicals$$aCD24 protein, human
000127437 7001_ $$aDyberg, Cecilia$$b1
000127437 7001_ $$aKrona, Cecilia$$b2
000127437 7001_ $$aVisse, Edward$$b3
000127437 7001_ $$aCarén, Helena$$b4
000127437 7001_ $$0P:(DE-HGF)0$$aNorthcott, Paul A$$b5
000127437 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b6$$udkfz
000127437 7001_ $$aStåhl, Nils$$b7
000127437 7001_ $$aPersson, Annette$$b8
000127437 7001_ $$aEnglund, Elisabet$$b9
000127437 7001_ $$aJohnsen, John I$$b10
000127437 7001_ $$aSiesjö, Peter$$b11
000127437 7001_ $$aDarabi, Anna$$b12
000127437 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-015-1758-5$$gVol. 123, no. 1, p. 1 - 13$$n1$$p1 - 13$$tJournal of neuro-oncology$$v123$$x1573-7373$$y2015
000127437 909CO $$ooai:inrepo02.dkfz.de:127437$$pVDB
000127437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127437 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127437 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000127437 9141_ $$y2015
000127437 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127437 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2015
000127437 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127437 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127437 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127437 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127437 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127437 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127437 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127437 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127437 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000127437 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000127437 980__ $$ajournal
000127437 980__ $$aVDB
000127437 980__ $$aI:(DE-He78)B062-20160331
000127437 980__ $$aUNRESTRICTED